Cellular & molecular immunology
Cure8 research brief
Why This Matters
The work suggests a new mechanism linking macrophage-driven ECM remodeling to protection of enteric neurons and reduced colitis in preclinical models, which could point to future therapies aimed at preventing neuronal loss in IBD.
For people with IBD, treatments that preserve enteric neurons might help limit long-term bowel dysfunction driven by neuronal injury.
Who Should Pay Attention
Researchers studying IBD pathogenesis, immune–neural interactions, and ECM biology; translational scientists developing novel IBD therapies; clinicians interested in future treatment targets; patients following experimental IBD research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This preclinical journal abstract reports that blocking the mAm methyltransferase PCIF1 in macrophages reduced colitis severity and prevented enteric neuronal loss in experimental models.
The authors link PCIF1 activity to suppression of a Znf219–Egr1 transcriptional program that controls extracellular matrix (ECM) remodeling; Pcif1 deficiency or pharmacologic PCIF1 blockade increased ECM deposition, promoted macrophage movement into neuronal plexuses, and supported neuronal maturation, which correlated with less inflammation-driven neuronal damage and milder colitis.
The study is presented at the molecular and cellular level in an animal or laboratory model (basic science). It identifies PCIF1 and the Znf219–Egr1 axis as mechanistic players and tests a pharmacologic PCIF1 blocker in the experimental system, but it does not report human clinical results.
The abstract suggests potential therapeutic relevance for preventing neuronal loss in IBD, not an established treatment. If you follow IBD research, this points to a new immune–neuron–ECM pathway that might be targeted in the future; however, findings from cellular/animal work require substantial further validation before clinical use.
Keep In Mind
This is a basic-science journal abstract (Cellular & Molecular Immunology) describing molecular and preclinical findings. It does not report human clinical trials or demonstrated patient benefits. Pharmacologic blockade was tested in the experimental system; safety and efficacy in humans remain unknown.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCellular & molecular immunology
AuthorsChenbo Ding, Jiachen Zhao, Tian Zhao +16 more
InstitutionInstitute for Immunology and Pathogenesis (IIP), Key Laboratory of Clinical Laboratory Diagnostics of Chinese Ministry of Education, Chongqing Medical University, Chongqing, China. chenbo.ding@cqmu.edu.cn.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 18, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Competing interests: RAF is an advisor to Glaxo Smith Kline, Celsius and is the recipient of a grant from Genetech/Roche. The authors declare that Hua-Bing Li, Chenbo Ding, Chen Luo, Jiachen Zhao, Shijie Chen, Xiao Liu, and Jing Zhou are the inventors on a patent application related to the application of PF007 and its derivatives in the treatment of intestinal inflammation (pending), which is relevant to the research concerning “PCIF1 is a potential therapeutic target for inhibiting intestinal inflammation” presented in this paper. The patent application has been disclosed to the journal, and the authors have provided an approved plan to manage any potential conflicts of interest arising from this arrangement. The remaining authors declare that they have no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Blocking the m6Am methyltransferase PCIF1 in macrophages attenuates colitis progression by preventing neuronal damage.
These results highlight a new cellular mechanism (macrophage-driven ECM changes) that may protect enteric neurons during intestinal inflammation — a process linked to symptoms and complications in IBD.
Citrullination of cathepsin H promotes NETs formation and exacerbates IBD via PI3K-Akt pathway.
The study identifies a new molecular mechanism (CTSH citrullination) that appears to drive NETs formation and worsen colitis in mice, which could point toward future therapies targeting PAD4–CTSH–NETs pathways. That...
Senkyunolide I Inhibits mtDNA‐cGAS‐STING Signaling in Macrophages via Targeting VDAC1 Oligomerization to Attenuate Ulcerative Colitis
The study identifies a new macrophage-driven immune pathway (VDAC1-mediated mtDNA release activating cGAS–STING) that contributes to ulcerative colitis in preclinical models and suggests a plant-derived compound (SEI)...